Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vitreoretinal Surgery PLLC

Neither a doctor nor a teaching hospital

Research payments

$5,135,708

775 payments

Through program year 2025, Vitreoretinal Surgery PLLC is reported as receiving $5,135,708 in research payments, across 775 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,975,344 513
2024 Research $776,804 95
2023 Research $1,168,769 88
2022 Research $1,211,450 77
2021 Research $3,341 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Genentech, Inc. $2,702,001 245 payments
  2. Ocular Therapeutix, Inc. $884,904 96 payments
  3. Regeneron Pharmaceuticals, Inc. $461,552 332 payments
  4. Apellis Pharmaceuticals, Inc. $416,530 43 payments
  5. EyePoint Pharmaceuticals US, Inc. $375,618 3 payments
  6. Janssen Research & Development, LLC $210,580 46 payments
  7. Roche TCRC, Inc. $77,886 5 payments
  8. AbbVie, Inc. $6,637 5 payments
Studies the money was for Research payments · program years 2021–2025
  1. Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $884,904 96 payments
  2. Port Delivery System of Ranibizumab Extension Study $763,533 69 payments
  3. Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $512,557 42 payments
  4. A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $461,552 332 payments
  5. Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $409,394 37 payments
  6. A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $375,618 3 payments
  7. A Phase III Study to Evaluate Faricimab in Patients With Central Retinal Vein Occlusion $359,093 16 payments
  8. A Phase III Study to Investigate Ro7200220 in Patients With Uveitic MacUlar Edema $272,313 34 payments
  9. A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular $183,671 39 payments
  10. An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $167,056 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record